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ABSTRACT
Objective: The aim of the present study is to synthesize novel benzimidazole derivatives as potent antifungal agents.
Methods: 2-chloromethyl-1H-benzimidazole has been synthesized by refluxing o-phenylenediamine with chloroacetic acid in the presence of 5N 
HCL. Further, N-substituted benzimidazole derivatives containing various heteroamines and aromatic compounds were synthesized. These, finally, 
prepared derivatives were kept for in vitro antifungal property.
Results: A novel series of antifungal agents, containing benzimidazole nucleus as a basic skeleton, has been synthesized.
Conclusion: The synthesized novel benzimidazole derivatives exhibit moderate activity (VMSA 1, 2, 8), some compounds showed significant activity 
(VMSA 6, 9, and 10), and compound VMSA 4 and 5 exhibits maximum activity.
Keywords: Benzimidazole, In vitro, Significant, Antifungal activity, Aromatic.
INTRODUCTION
The fungi are more gradually developed form of organism when 
compared to unicellular organism such as bacteria, viruses, and prions. 
The fungi are classified as eukaryotes which have nuclear membrane 
that surrounds the nucleus. The fungi have complex structural features 
due to genetic and morphological complexity [1,2].
It is observed that, among all the different microbes available, fungi 
have a tremendous impact on the immunocompromised patients and 
which is emerged as a major infection [3].
There has been significant progress in developing and implementing 
strategies for the development of new antifungal agents. One strategy 
for antifungal drug development besides the classical screening of 
many classes of synthetic or natural products against a variety of fungi 
involves the use of the molecular biological revolution. It is now possible 
to identify molecular targets that are essential for fungal virulence. The 
identification of unique genes and their signaling network, important 
to the path biology of fungi, could translate into their use as molecular 
targets for drug development. There are, now, a series of molecular 
techniques to identify gene expression(s) under certain conditions, 
and the field of molecular pathogenesis has matured to the point that 
validation for these potential “virulence” targets can be achieved [4-7].
Furthermore, area of cell biology is now being focused, within pathogenic 
fungi, and uses all the molecular and biochemical tools and understanding 
to dissect it, and thereby, attempt was taken for selecting specific fungicidal 
objects having different selectivity with mammalian cells. Many potential 
objects for antifungal drug development have been recognized [8].
These can vary from the azoles which inhibit cyt.P450-dependent 
endoplasmic reticulum where ergosterol gets biosynthesized. A certain 
antifungal agent such as Amphotericin B which attach to ergosterol 
inducing conformational change with formation of ionic pores. 
Echinocandins inhibit 1, 3-β-D glucan synthesis induced by β-1, 3 
glucan synthesis [9,10].
Although currently therapeutic choice for the use of invasive fungal 
infection has some limits, most of antifungal compounds are not too 
specific due to resistance development, toxicity of host, and side effects 
which are undesirable [11]. The azole category of antifungal drugs has 
different agents which are under various clinical phases. These azole 
category drugs inhibit membrane-bound enzyme. The selected objects 
of azoles are cyt.P450 and lanosterol-14 demethylase [12]. Ergosterol 
biosynthesis was inhibited due to azoles which directly reduce the 
fungal growth by the binding of active sites with azoles [13]. The 
biosynthesis of plant phytosterol, animal cholesterol, and fungal sterol 
create an intermediate step due to hemoprotein [14].
As azoles and their derivatives are the most important class of the 
aromatic heterocyclic compounds exhibiting a wide range of biological 
applications, especially as active moieties in first-, second-, and third-
generation azoles which act as antifungal agents such as miconazole, 
econazole, fluconazole, itraconazole, and voriconazole, we were now in 
position for exploring further possibilities in azoles compounds [15,16].
Structural modification has shown that the azole compounds also 
exhibit properties such as antibacterial [17], anticonvulsant [18,19], 
anticancer [20,21], anti-inflammatory [22,23], antimalarial [24], 
antineoplastic [25], insecticidal, and herbicidal [26].
METHODS
1. The chemicals necessary for the study were purchased from Merck 
and they were purified before use.
2. Campbell melting point apparatus was used for determining melting 
point of synthesized compounds.
3. The thin-layer chromatographic method was used where Silica Gel-G 
was selected for the preparation of thin-layer chromatography (TLC) 
plates.
4. TLC plates gets visualized under iodine vapors or observed below 
UV light.
5. “SHIMADZU 3100” and “JASCO 530V” were used for determining 
infrared spectra. CDCl3/dimethyl sulfoxide (DMSO) was used for 
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determining 1H-nuclear magnetic resonance spectra where standard 
selected is tetramethylsilane (Schemes 1 and 2).
Antifungal property of synthesized compound
The antifungal activity of the synthesized compounds was carried 
out using well-plate method, and minimum inhibitory concentrations 
(MIC) values were calculated as µg/ml. The compounds were tested 
against Candida albicans, Penicillium notatum, Aspergillus niger, and 
Aspergillus fumigatus.
Stock solutions of the synthesized derivatives were prepared in DMSO. 
Dilution series using sterile water were prepared from 12.5 µg/ml to 
100 µg/ml in microtest tubes. Suspension of test organism was freshly 
prepared in 1 ml of sterile normal saline solution and was standardized 
spectrophotometrically to 107 CFU/ml.
RESULTS AND DISCUSSION
A novel series of antifungal agents, containing benzimidazole nucleus 
as a basic skeleton, has been synthesized. The antifungal testing of 
synthesized compounds was carried out using A. niger, C. albicans, 
A. fumigatus, and P. notatum as a strain.
Among synthesized compounds, VMSA 1, 2, and 8 (MIC=100 µg/mL) 
and 3 and 7 (MIC=50 µg/mL) exhibit significant activity against 
C. albicans, whereas compounds VMSA 6, 9, and 10 (MIC=25 µg/
mL) showed significant activity. VMSA 4 and 5 show greater 
activity (MIC=12.5 µg/mL) compared with MIC of the ketoconazole 
(Tables 1 and 2).
CONCLUSION
From the literature survey, it was found that there has been a lot of 
research going in the field of novel antifungal drug development. 
It was found that many antifungal agents contain benzimidazole 
moieties in their structure. Therefore, benzimidazole was selected 
for the development of new chemical entities as potential antifungal 
agents.
Ten benzimidazole derivatives containing heteroamines and aromatic 
compounds were prepared. The prepared compounds were confirmed 
by different spectroscopic and chromatographic techniques.
Well plate method was used for testing in vitro antifungal activity of 
ten synthesized compounds. These activities were observed in agar 
culture plates in the form of zone of inhibition which was recorded in 
Scheme 1: Preparation of chloromethyl substituted benzimidazole compound
Scheme 2: Synthesis of 2-chloromethyl-1H-benzimidazole derivatives
Code R Molecular formula % Yield Molecular pressure (°C) Rf value
VMSA1 C15H13N3O2 70 146–148 0.65
VMSA2 C15H13N3O2 51 140–142 0.56
Table 1: Physicochemical study of 2-chloromethyl-1H-benzimidazole derivatives
(Contd...)
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Code R Molecular formula % Yield Molecular pressure (°C) Rf value
VMSA3 C14H12N3Cl 53 155–157 0.58
VMSA4 C11H9N5O2 65 118–120 0.62
VMSA5 C10H10N6 61 158–160 0.68
VMSA6 C15H13N3O2 52 163–165 0.58
VMSA7 C14H12N3Cl 56 98–100 0.62
VMSA8 C15H15N3 69 82–84 0.55
VMSA9 C15H12ClN3O2 53 180–182 0.70
VMSA10 C15H15N3 47 158–160 0.67
Table 1: (Continued)
centimeters. Compounds VMSA 1, 2, and 8 and VMSA 3 and 7 showed 
intense activity against C. albicans, whereas compounds VMSA 6, 9, and 
10 exhibit greater activity. VMSA 4 and 5 exhibit maximum activities 
with MIC compared to that of the ketoconazole.
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Table 2: In vitro antifungal activity of benzimidazole 
derivatives (MIC data for prepared derivatives)












MIC: Minimum inhibitory concentrations
